Fluidigm Corporation (FLDM) : Traders are negative on Fluidigm Corporation (FLDM), as it has 10% of short positions outstanding compared to its float. The total shorts have reduced by -248,283 shares, which is a -8.4% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,2,959,921 to 2,711,638 shares. While the daily trading volume of the stock is 231,539, there are 12 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Fluidigm Corporation (NASDAQ:FLDM): The stock opened at $9.11 on Wednesday but the bulls could not build on the opening and the stock topped out at $9.35 for the day. The stock traded down to $9.00 during the day, due to lack of any buying support eventually closed down at $9.06 with a loss of -2.79% for the day. The stock had closed at $9.32 on the previous day. The total traded volume was 243,668 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (PRESIDENT & CEO) of Fluidigm Corp, Worthington Gajus Vincent had sold 6,000 shares worth of $69,000 in a transaction dated November 3, 2015. In this transaction, 6,000 shares were sold at $11.5 per share.
Fluidigm Corporation creates, manufactures and market technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Companys core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions, clinical laboratories, pharmaceutical, biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools, including analytical and preparatory systems for genomic and proteomic analysis, and consumables, including Integrated Fluidic Circuits (IFCs), assays, and reagents. The Companys products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers, and Maxpar Reagents, among others.